Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
37.19
-0.29 (-0.77%)
At close: May 18, 2026, 4:00 PM EDT
36.71
-0.48 (-1.29%)
Pre-market: May 19, 2026, 5:15 AM EDT
Alkermes Employees
Alkermes had 2,050 employees as of December 31, 2025. The number of employees increased by 250 or 13.89% compared to the previous year.
Employees
2,050
Change (1Y)
250
Growth (1Y)
13.89%
Revenue / Employee
$762,098
Profits / Employee
$74,498
Market Cap
6.20B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,050 | 250 | 13.89% |
| Dec 31, 2024 | 1,800 | -300 | -14.29% |
| Dec 31, 2023 | 2,100 | -180 | -7.89% |
| Dec 31, 2022 | 2,280 | 69 | 3.12% |
| Dec 31, 2021 | 2,211 | -34 | -1.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Dr. Reddy's Laboratories | 27,811 |
| Elanco Animal Health | 9,900 |
| Amneal Pharmaceuticals | 8,700 |
| Hims & Hers Health | 2,442 |
| Neurocrine Biosciences | 2,000 |
| Lantheus Holdings | 1,193 |
| Supernus Pharmaceuticals | 778 |
| BioCryst Pharmaceuticals | 435 |
ALKS News
- 5 days ago - Alkermes price target raised to $48 from $45 at Baird - TheFly
- 6 days ago - Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study - TheFly
- 6 days ago - Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia - Business Wire
- 12 days ago - Alkermes price target raised to $48 from $42 at UBS - TheFly
- 12 days ago - Alkermes price target raised to $50 from $45 at Needham - TheFly
- 13 days ago - Alkermes Earnings Call Transcript: Q1 2026 - Transcripts
- 13 days ago - Alkermes reports Q1 EPS (40c) vs 13c last year - TheFly
- 13 days ago - Alkermes sees FY26 revenue $1.73B-$1.84B, consensus $1.8B - TheFly